Law Firm Probes Forte, Luxfer, Huntsman and Olin Merger Terms

The firm is currently reviewing the $77.00 per share cash sale of Forte Biosciences to argenx and the $17.37 per share acquisition of Luxfer Holdings by affiliates of Wynnchurch Capital. Additionally, investigators are examining the stock-for-stock merger between Huntsman Corporation and Olin Corporation. Under the proposed terms, Huntsman shareholders would receive 0.5476 shares of Olin, leaving Olin investors with approximately 54.5% ownership of the combined entity.

Attorneys at Halper Sadeh suggest these proposed deals may include restrictive terms that stifle superior competing offers or disadvantage non-insider investors. The firm, led by Daniel Sadeh and Zachary Halper, aims to secure increased compensation or enhanced disclosures for those holding positions in these companies. Legal representatives indicated they are operating on a contingent fee basis, meaning shareholders would not face out-of-pocket expenses for the inquiry.